Benitec licenses RNAi to Merck
05 July, 2004 by Melissa TrudingerBrisbane-based Benitec (ASX: BLT) has granted a non-exclusive research licence to Merck & Co, giving permission for Merck to use its DNA-directed RNAi (ddRNAi) technology in research activities.
Cytokine key to smallpox infection
02 July, 2004 by Staff WritersScientists at the Australian National University (ANU) have identified the immune response that determines why some mice are infected with mousepox and others are not, a discovery that could lead to better protection for humans in a bio-terror attack.
Norwood Immunology lists in UK at a premium
02 July, 2004 by Renate KrelleNorwood Immunology (AIM:NIM) commenced trading yesterday on London's Alternative Investment Market (AIM), with shares closing at 40.5 pence (AUD$1.046), a premium to their issue price of 38 pence.
Biotechs gear up for new 'best practice' rules
02 July, 2004 by Melissa TrudingerIn this financial year's upcoming crop of annual reports, ASX-listed companies will have to include a section disclosing their adherence to the 10 essential corporate governance principles developed in 2002 by the exchange's corporate governance council as a framework for best practice.
Ventracor, Agenix grab grants
01 July, 2004 by Renate KrelleSydney artificial heart company Ventracor (ASX:VCR) scooped up AUD$1.2 million in funding today, when the second round of Australian Research Council (ARC) linkage grants were announced.
Blue day as Florigene and Suntory unveil a biotech holy grail
01 July, 2004 by Melissa TrudingerIt has taken 15 years, but Australian company Florigene and its Japanese parent Suntory say they have succeeded in creating the holy grail of floristry -- the blue rose.
Amrad halts buyback during Avexa spin-out
01 July, 2004 by Melissa TrudingerAmrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.
Stirling products to test growth promotors in sheep.
30 June, 2004 by Renate KrellePerth-based Stirling Products (ASX:STI) is preparing for the first animal trials of its ST810 growth promotion agent in sheep.
AGT Biosciences changes name to Chemgenex
29 June, 2004 by Melissa TrudingerAGT Biosciences has completed the last step in its merger with ChemGenex Therapeutics with the official name change of the company going through. Approval by AGT shareholders was obtained last week at an EGM.
Eiffel to collaborate with Singapore company
29 June, 2004 by Melissa TrudingerEiffel Technologies (ASX: EIF) has signed an agreement with Singapore company NanoMaterials Technology to jointly develop new technology for drug reengineering.
Regenera in diabetes patent deal
29 June, 2004 by Renate KrellePerth-based opthamology specialist Regenera (ASX: RGA) today extended its IP portfolio, announcing the assignment on an Australian provisional patent to its subsdiary Retmed.
NZ's Proacta stitches up $11.5 million in venture capital
28 June, 2004 by Graeme O'NeillAuckland anti-cancer drug developer Proacta Therapeutics is celebrating after stitching together a venture-capital deal to begin human clinical trials of two of its lead compounds next year.
GTG supplies non-coding patents to NZ’s Ovita
28 June, 2004 by Graeme O'NeillMelbourne gene-test company Genetic Technologies (ASX:GTG) has granted a license to New Zealand agbiotech company Ovita Limited to apply GTG’s non-coding DNA patents to its own internal activities.
Agenix settles Synbiotics litigation
28 June, 2004 by Melissa TrudingerAgenix (ASX: AGX) subsidiary Agen Biomedical has agreed to settle its litigation with its former US distributor Synbiotics over alleged infringements of Synbiotics' canine heartworm diagnostics and related supply contract issues.
BioTech Capital takes punt on meditech firm
28 June, 2004 by Renate KrelleSydney-based pooled development fund BioTech Capital (ASX:BTC) has dipped its toe into the medical device sector with a $2 million investment in Continence Control Systems (CCS).
